Co-Authors
This is a "connection" page, showing publications co-authored by VAN KARLYLE MORRIS and SHUBHAM PANT.
Connection Strength
0.105
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
Score: 0.057
-
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
Score: 0.049